Veru Adds Financial Advisor to Pursue Alternatives for Female Health Business
Veru Adds Financial Advisor to Pursue Alternatives for Female Health Business
DJ Veru Adds Financial Advisor to Pursue Alternatives for Female Health Business
By Chris Wack
Veru Inc. said Monday it has engaged Morgan Stanley & Co. as a financial advisor to assist it in pursuing strategic alternatives regarding its legacy FC2 Female Condom/FC2 Internal Condom business.
The biopharmaceutical company said it considers now a good time to consider alternatives for the business, with the last two consecutive quarters for its FHC business having set records in terms of revenues and profit.
Veru said that with the potential for five registration clinical trials in calendar year 2021, it has transformed itself into a late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC business isn't as strong as it once was.
The company said it is open to exploring the right kind of strategic transaction for the FHC business with a view toward the best, long-term interests of its shareholders, which may include continuing to operate the FHC business.
Veru shares were up 8% to $13.25 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 08, 2021 09:18 ET (14:18 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Veru Adds Financial Advisor to Pursue Alternatives for Female Health Business
DJ Veru增加財務顧問為女性健康業務尋找替代方案
By Chris Wack
克里斯·瓦克(Chris Wack)著
Veru Inc. said Monday it has engaged Morgan Stanley & Co. as a financial advisor to assist it in pursuing strategic alternatives regarding its legacy FC2 Female Condom/FC2 Internal Condom business.
維魯公司週一表示，它已聘請摩根士丹利公司作為財務顧問，協助其尋找傳統的FC2女用避孕套/FC2內部避孕套業務的戰略選擇。
The biopharmaceutical company said it considers now a good time to consider alternatives for the business, with the last two consecutive quarters for its FHC business having set records in terms of revenues and profit.
這家生物製藥公司表示，它認為現在是考慮該業務替代方案的好時機，其FHC業務連續兩個季度在收入和利潤方面創下紀錄。
Veru said that with the potential for five registration clinical trials in calendar year 2021, it has transformed itself into a late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC business isn't as strong as it once was.
Veru表示，隨着2021年有可能進行5項註冊臨牀試驗，該公司已轉型為一家後期臨牀生物製藥公司，因此與FHC業務的戰略契合度不像以前那麼強。
The company said it is open to exploring the right kind of strategic transaction for the FHC business with a view toward the best, long-term interests of its shareholders, which may include continuing to operate the FHC business.
該公司表示，它願意為FHC業務探索合適的戰略交易，以期實現股東的最佳長期利益，其中可能包括繼續運營FHC業務。
Veru shares were up 8% to $13.25 in premarket trading.
Veru股價在盤前交易中上漲8%，至13.25美元。
Write to Chris Wack at chris.wack@wsj.com
寫信給克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道瓊通訊社
March 08, 2021 09:18 ET (14:18 GMT)
2021年3月8日09：18美國東部時間(格林尼治標準時間14：18)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧